Rapid eye movement (REM) sleep behavior disorder (RBD) is a prodromal condition for Parkinson's disease (PD) and other synucleinopathies, which often occurs many years before the onset of PD. We analyzed 261 RBD patients and 379 controls for nine PD-associated SNPs and examined their effects, first upon on RBD risk and second, on eventual progression to synucleinopathies in a prospective follow-up in a subset of patients. The SCARB2 rs6812193 (OR = 0.67, 95 % CI = 0.51-0.88, p = 0.004) and the MAPT rs12185268 (OR-0.43, 95 % CI-0.26-0.72, p = 0.001) were associated with RBD in different models. Kaplan-Meier survival analysis in a subset of RBD patients (n = 56), demonstrated that homozygous carriers of the USP25 rs2823357 SNP had progressed to synucleinopathies faster than others (log-rank p = 0.003, Breslow p = 0.005, Tarone-Ware p = 0.004). As a proof-of-concept study, these results suggest that RBD may be associated with at least a subset of PD-associated genes, and demonstrate that combining genetic and prodromal clinical data may help identifying individuals that are either more or less susceptible to develop synucleinopathies. More studies are necessary to replicate these results, and identify more genetic factors affecting progression from RBD to synucleinopathies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12031-015-0569-7 | DOI Listing |
Brain
March 2025
Krembil Brain Institute, University Health Network, Toronto, ON M5T 1M8, Canada.
Parkinson's disease is characterized, in part, by hypoactivity of direct pathway inhibitory projections from striatum to the globus pallidus internus (GPi) and indirect pathway inhibitory projections from globus pallidus externus (GPe) to the subthalamic nucleus (STN). In people with Parkinson's disease (n=32), we explored the potential use of intracranial stimulation for eliciting long-term potentiation (LTP) of these underactive pathways to produce improvement of symptoms that persists beyond stimulation cessation. During GPi deep brain stimulation (DBS) surgery, we found strong evidence (p<.
View Article and Find Full Text PDFReprod Sci
March 2025
Departments of Obstetrics and Gynecology and Biochemistry and Molecular Biology, the C.S. Mott Center for Human Growth and Development, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
Glyphosate-based herbicides (GBHs) are the most widely used herbicides in the United States, accounting for 19% of estimated global use. Although the Environmental Protection Agency (EPA) has reaffirmed that the active ingredient glyphosate (GLY) is safe for humans, recent studies on exposure have suggested association with cancer, metabolic disorders, endocrine disruption and infertility, Alzheimer's and Parkinson's disease, and psychological disorders. Current literature on the effects of GLY exposure on reproductive function suggests potential clinical implications on women's reproductive health, including polycystic ovarian syndrome (PCOS), endometriosis, infertility, and adverse pregnancy outcomes.
View Article and Find Full Text PDFMetab Brain Dis
March 2025
Xinxiang Key Laboratory of Targeted Intervention for Brain Cell Injury, Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China.
Parkinson's disease (PD) is a chronic neurodegenerative condition marked by the gradual degeneration of dopaminergic neurons, resulting in a range of disabling motor and non-motor symptoms. Despite advances, the molecular mechanisms underlying PD remain elusive, and effective biomarkers and therapeutic targets are limited. Recent studies suggest that mitochondrial dysfunction and dysregulated cellular metabolism are central to PD pathogenesis.
View Article and Find Full Text PDFJ Neurol
March 2025
Centre for Neurology, Department of Neurodegenerative Diseases, and Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
Next-generation neurostimulators capable of running closed-loop adaptive deep brain stimulation (aDBS) are about to enter the clinical landscape for the treatment of Parkinson's disease. Already promising results using aDBS have been achieved for symptoms such as bradykinesia, rigidity and motor fluctuations. However, the heterogeneity of freezing of gait (FoG) with its wide range of clinical presentations and its exacerbation with cognitive and emotional load make it more difficult to predict and treat.
View Article and Find Full Text PDFJ Neurol
March 2025
Department of Clinical Research in Neurology, Center for Neurodegenerative Diseases and the Aging Brain, University of Bari 'Aldo Moro', "Pia Fondazione Cardinale G. Panico", Via San Pio X, 73039, Tricase, Lecce, Italy.
Background: Fatigue is a common non-motor symptom (NMS) in Parkinson's disease (PD), affecting up to 50% of patients. It is suggested that PD-related fatigue may contribute to the burden perceived by caregivers.
Objective: This study aims to evaluate the impact of PD-related fatigue on caregiver burden.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!